ArticleJournal of proteome research2015
Pharmaceutical relevant cytokine receptors: lessons from the first drafts of the human proteome.
Article in Journal of proteome research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although a plethora of human proteins are ubiquitously expressed, several proteins with high pharmaceutical relevance show a tissue- or cell-type specific expression pattern. Science across all disciplines, ranging from developmental biology to personalized medicine, would benefit from detailed knowledge about this so-called human proteome. Two recent publications in Nature use large-scale proteomics to create first drafts of the human proteome, which are freely accessible online. In this Letter, we analyze the proteomic data with regard to the expression of three different cytokine receptors, the Tumor Necrosis Factor (TNF)α Receptor I (TNFRSF1A) and II (TNFRSF1B) and the Interleukin-6 Receptor (IL-6R). Therapeutic inhibition of these proteins is highly effective in a high number of inflammatory diseases, and TNFα blocking agents alone were sold for almost $30 billion in 2013. We find that the known expression pattern of the three receptors is not reflected in the current drafts of the human proteome, as the proteomics data fail to detect protein expression in several cell types and tissues which are known to express these cytokine receptors. Thus, our results suggest that the current drafts of the human proteome are far from complete, and that the data have to be used with caution especially in terms of personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.